Treatment Resistant Depression Global Clinical Trials Review, H2, 2019
- GDHC5221CTIDB
- Pages: 229
- December 2019
- Total Views:1147
- Region : Global
- GlobalData
- Market Research Report
Details
Treatment Resistant Depression Global Clinical Trials Review, H2, 2019
Summary
GlobalData's clinical trial report, Treatment Resistant Depression Global Clinical Trials Review, H2, 2019" provides an overview of Treatment Resistant Depression clinical trials scenario. This report provides top line data relating to the clinical trials on Treatment Resistant Depression. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Content
Scope
Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Treatment Resistant Depression Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Treatment Resistant Depression 31
Oct 15, 2019: Relmada Therapeutics announces top-line results from REL-1017 phase 2 study in individuals with treatment resistant depression 31
Oct 14, 2019: Relmada Therapeutics to announce results of phase 2 study of REL-1017 for treatment resistant depression and conduct Conference Call 31
Clinical Trial Profile Snapshots 32
Appendix 228
Abbreviations 228
Definitions 228
Research Methodology 229
Secondary Research 229
About GlobalData 230
Contact Us 230
Source 231
List Of Figure
List of Figures
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Treatment Resistant Depression Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
Treatment Resistant Depression Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 11
Treatment Resistant Depression Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 12
Treatment Resistant Depression Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 13
Treatment Resistant Depression Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019* 14
Treatment Resistant Depression Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019* 15
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 16
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 19
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Phase (%), 2019* 22
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 23
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
Treatment Resistant Depression Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
Treatment Resistant Depression Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 27
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 28
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 29
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 30
GlobalData Methodology 229
List Of Table
List of Tables
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Region, 2019* 8
Treatment Resistant Depression Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
Treatment Resistant Depression Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 11
Treatment Resistant Depression Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 12
Treatment Resistant Depression Therapeutics Clinical Trials, North America, Top Countries, 2019* 13
Treatment Resistant Depression Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 14
Treatment Resistant Depression Therapeutics Clinical Trials, Central and South America, Top Countries, 2019* 15
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 16
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 19
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Phase, 2019* 22
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 23
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
Treatment Resistant Depression Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
Treatment Resistant Depression Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 27
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 28
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 29
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 30
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Companies
Johnson & Johnson
F. Hoffmann-La Roche Ltd
AstraZeneca Plc
Bristol-Myers Squibb Co
Eli Lilly and Co
Alkermes Plc
The Lundbeck Foundation
Evotec SE
Relmada Therapeutics Inc
BrainCells Inc
Company Profile
Company Profile Title
Treatment Resistant Depression Global Clinical Trials Review, H2, 2019
Summary
GlobalData's clinical trial report, Treatment Resistant Depression Global Clinical Trials Review, H2, 2019" provides an overview of Treatment Resistant Depression clinical trials scenario. This report provides top line data relating to the clinical trials on Treatment Resistant Depression. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Treatment Resistant Depression Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Treatment Resistant Depression 31
Oct 15, 2019: Relmada Therapeutics announces top-line results from REL-1017 phase 2 study in individuals with treatment resistant depression 31
Oct 14, 2019: Relmada Therapeutics to announce results of phase 2 study of REL-1017 for treatment resistant depression and conduct Conference Call 31
Clinical Trial Profile Snapshots 32
Appendix 228
Abbreviations 228
Definitions 228
Research Methodology 229
Secondary Research 229
About GlobalData 230
Contact Us 230
Source 231
List Of Figure
List of Figures
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Treatment Resistant Depression Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
Treatment Resistant Depression Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 11
Treatment Resistant Depression Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 12
Treatment Resistant Depression Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 13
Treatment Resistant Depression Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019* 14
Treatment Resistant Depression Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019* 15
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 16
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 19
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Phase (%), 2019* 22
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 23
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
Treatment Resistant Depression Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
Treatment Resistant Depression Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 27
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 28
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 29
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 30
GlobalData Methodology 229
List Of Table
List of Tables
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Region, 2019* 8
Treatment Resistant Depression Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
Treatment Resistant Depression Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 11
Treatment Resistant Depression Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 12
Treatment Resistant Depression Therapeutics Clinical Trials, North America, Top Countries, 2019* 13
Treatment Resistant Depression Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 14
Treatment Resistant Depression Therapeutics Clinical Trials, Central and South America, Top Countries, 2019* 15
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 16
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
Treatment Resistant Depression Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
Proportion of Treatment Resistant Depression to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 19
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
Treatment Resistant Depression Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Phase, 2019* 22
Treatment Resistant Depression Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 23
Treatment Resistant Depression Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
Treatment Resistant Depression Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
Treatment Resistant Depression Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 27
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 28
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 29
Treatment Resistant Depression Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 30
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Companies
Johnson & Johnson
F. Hoffmann-La Roche Ltd
AstraZeneca Plc
Bristol-Myers Squibb Co
Eli Lilly and Co
Alkermes Plc
The Lundbeck Foundation
Evotec SE
Relmada Therapeutics Inc
BrainCells Inc
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020